Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Merck's anti-TL1A antibody secures a win in ph. 2 hidradenitis suppurativa trial

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 1 October 2026 · Fusion42 review

Merck's anti-TL1A antibody tulisokibart demonstrated positive results in a phase 2b trial for moderate to severe hidradenitis suppurativa, meeting primary and secondary endpoints and prompting advancement toward phase 3 development.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You should prepare for new competition in hidradenitis suppurativa treatments as Merck advances tulisokibart into phase 3 trials, offering an alternative mechanism against a disease with limited options.

◆ Coverage

1 source · 30 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialimmunologyautoimmune-diseasepharma-rddrug-development